Jenny O’Nions

1.8k citations

27 papers · 1.2k indexed · 1 hit paper · h-index 14

Oncology top 5%
- Cancer-related Molecular Pathways 7
- Viral-associated cancers and disorders 6
Biotechnology top 5%
- Cancer Research and Treatments 4
Cancer Research top 10%
Molecular Biology
- Protein Degradation and Inhibitors 4
Otorhinolaryngology top 10%
Hematology
- Acute Myeloid Leukemia Research 9
- Multiple Myeloma Research and Treatments 4
Pathology and Forensic Medicine
- Lymphoma Diagnosis and Treatment 4
Genetics
- Myeloproliferative Neoplasms: Diagnosis and Treatment 3

Co-authors: Martin J. Allday Louise Brooks Tim Crook John Tidy María C. Marín William G. Kaelin Catherine Harwood John M. Nicholls
Cited by: Oncology Biotechnology Cancer Research
Journals: Nature Genetics (1 paper)Journal of Clinical Oncology (1 paper)Blood (7 papers)
Partner nations: United Kingdom Australia United States

In The Last Decade

Jenny O’Nions

26 papers receiving 1.1k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by Jenny O’Nions

Since Specialization

Citations

This map shows the geographic impact of Jenny O’Nions's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jenny O’Nions with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jenny O’Nions more than expected).

Fields of papers citing papers by Jenny O’Nions

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jenny O’Nions. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jenny O’Nions. The network helps show where Jenny O’Nions may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Jenny O’Nions, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Jenny O’Nions Line = papers co-authored together Jenny O’Nions links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Diagnosis and treatment of T/myeloid mixed phenotype acute leukaemia (T/M‐MPAL) eJHaem ·Ke Xu,Enas Abusalim,Evan Vitsaras,Karen Orfinada,Robert Baker,Elisabeth P. Nacheva,Andrew J. Wilson,Jenny O’Nions,Rajeev Gupta	2025	0
2	Pretransplant MRD detection of fusion transcripts is strongly prognostic in KMT2A-rearranged acute myeloid leukemia Blood ·Sun Loo,Nicola Potter,Adam Ivey,Jenny O’Nions,R C Moon,Jelena Jovanović,Chun Yew Fong,Natasha S. Anstee,Ing Soo Tiong,Jad Othman,Chong Chyn Chua,H W Renshaw,Robert Baker,Shaun Fleming,Nigel H. Russell,David Ritchie,Ashish Bajel,Hsin‐An Hou,Richard Dillon,Andrew H. Wei	2024	4
3	P574: DIAGNOSIS AND TREATMENT OF T/MYELOID MIXED PHENOTYPE ACUTE LEUKAEMIA (T/M-MPAL)- A UK SINGLE CENTRE EXPERIENCE HemaSphere ·Enas Abusalim,Evan Vitsaras,Karen Orfinada,Baker Robert,Elisabeth P. Nacheva,Andrew J. Wilson,Jenny O’Nions,Gupta Rajeev,Ke Xu	2023	1
4	Cardiovascular risk in a contemporary cohort of patients with myeloproliferative neoplasms’ Current Research in Translational Medicine ·Dipal Mehta,Samah Alimam,Donal P. McLornan,John A. Henry,Syeda Ahmed,Arjun K. Ghosh,Sara Tyebally,John M. Walker,Riyaz S. Patel,Rodothea Amerikanou,Jenny O’Nions,Andrew J. Wilson,Jon Lambert,Mallika Sekhar,Daniel Chen	2023	5
5	Tolerability and Clinical Activity of Novel First in Class Oral Agent, Inobrodib (CCS1477), in Combination with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma Blood ·Emma Searle,James Cavet,Victoria Campbell,Steven Knapper,Ceri Bygrave,Dima El‐Sharkawi,Charlotte Pawlyn,Maria Creignou,Harriet S. Walter,David Valcárcel,Marta Hidalgo Soto,Jenny O’Nions,Amrutha Sridhar,Tomasz Knurowski,Karen Clegg,Neil Pegg,Will West,Debbie Haynes,Kris Frese,Tim C. P. Somervaille	2023	1
6	EP0042, a Dual FLT3 and Aurora Kinase Inhibitor: Preliminary Results of an Ongoing Phase I/IIa First in Human Study in Patients with Relapsed/Refractory Acute Myeloid Leukemia Blood ·David Taussig,Jenny O’Nions,Mojca Jongen‐Lavrencic,Jeroen Janssen,David C. de Leeuw,Peter Tan,Sue Brook,Katie Stoddart,Hendrik‐Tobias Arkenau,Geoff Fisher	2022	1
7	Single Centre Analysis of JAK2 V617F and Exon 12 Negative Idiopathic Erythrocytosis Blood ·Kushani Ediriwickrema,Andrew J. Wilson,Jenny O’Nions,Mallika Sekhar,Syeda Ahmed,Aisha Roble,Emma Louise Shambrook,Jonathan Lambert,Samah Alimam	2021	2
8	Characterization of response and corneal events with extended follow-up after belantamab mafodotin (GSK2857916) monotherapy for patients with relapsed multiple myeloma: a case series from the first-time-in-human clinical trial Haematologica ·Rakesh Popat,Dana Warcel,Jenny O’Nions,Anna Cowley,Sasha Smith,William Tucker,Kwee Yong,Simona Degli Esposti	2020	36
9	Durability of Response and Characterisation of Corneal events with Extended follow-up after Belantamab Mafodotin monotherapy for patients with relapsed/refractory Multiple Myeloma Clinical Lymphoma Myeloma & Leukemia ·Rakesh Popat,Dana Warcel,Jenny O’Nions,Anna Cowley,Sasha Smith,Kwee Yong,Simona Degli Esposti	2019	1
10	A complex neurological presentation of syphilis BMJ Case Reports ·Max Kamath,Maleeha Rizvi,Jenny O’Nions,Gary Brook	2013	6
11	Epstein-Barr Virus Selectively Deregulates DNA Damage Responses in Normal B Cells but Has No Detectable Effect on Regulation of the Tumor Suppressor p53 Journal of Virology ·Jenny O’Nions,Abigail Turner,Richard A. Craig,Martin J. Allday	2006	20
12	Transcriptional silencing of Polo-like kinase 2(SNK/PLK2)is a frequent event in B-cell malignancies Blood ·Nelofer Syed,Paul J. Smith,Alexandra Sullivan,Lindsay C. Spender,Martin J.S. Dyer,Lorraine Karran,Jenny O’Nions,Martin J. Allday,Ingrid Hoffmann,Dorothy H. Crawford,Beverley E Griffin,Paul J. Farrell,Tim Crook	2005	94
13	Deregulation of the Cell Cycle by the Epstein–Barr Virus Advances in cancer research ·Jenny O’Nions,Martin J. Allday	2004	24
14	Proliferation and differentiation in isogenic populations of peripheral B cells activated by Epstein–Barr virus or T cell-derived mitogens Journal of General Virology ·Jenny O’Nions,Martin J. Allday	2004	25
15	Epstein–Barr virus can inhibit genotoxin-induced G1 arrest downstream of p53 by preventing the inactivation of CDK2 Oncogene ·Jenny O’Nions,Martin J. Allday	2003	25
16	Relationship Between p53 Codon 72 Polymorphism and Susceptibility to Sunburn and Skin Cancer Journal of Investigative Dermatology ·Jane McGregor,Catherine Harwood,Louise Brooks,Déirdre Kelly,Jenny O’Nions,Antony R. Young,Thiru Surentheran,Judith Breuer,Thomas P. Millard,Cathryn M. Lewis,Irene M. Leigh,Alan Storey,Timothy Crook,Sheila Fisher	2002	77
17	E7 proteins from oncogenic human papillomavirus types transactivate p73: role in cervical intraepithelial neoplasia British Journal of Cancer ·L. Brooks,Alice Sullivan,Jenny O’Nions,Alison M. Bell,B Dunne,John Tidy,David J. Evans,Pinchas Osin,Karen H. Vousden,B.A. Gusterson,Paul J. Farrell,Alan Storey,Milena Gasco,Toshiyuki Sakai,Timothy Crook	2002	27
18	p73 is over-expressed in vulval cancer principally as the Δ2 isoform British Journal of Cancer ·Jenny O’Nions,L. Brooks,Alice Sullivan,Alison M. Bell,B Dunne,M. Rozycka,A. Rama Mohan Reddy,John Tidy,David J. Evans,Paul J. Farrell,Abigail Evans,Milena Gasco,B.A. Gusterson,Tim Crook	2001	46
19	High level expression of ΔN-p63: a mechanism for the inactivation of p53 in undifferentiated nasopharyngeal carcinoma (NPC)? Oncogene ·Tim Crook,John M. Nicholls,Louise Brooks,Jenny O’Nions,Martin J. Allday	2000	162
20	A common polymorphism acts as an intragenic modifier of mutant p53 behaviourbreakdown → Nature Genetics ·María C. Marín,Christine A. Jost,Louise Brooks,Meredith S. Irwin,Jenny O’Nions,John Tidy,Nicholas D. James,Jane McGregor,Catherine Harwood,Işık G. Yuluğ,Karen H. Vousden,Martin J. Allday,Barry A. Gusterson,Shuntaro Ikawa,Philip W. Hinds,Tim Crook,William G. Kaelin	2000	442

About Jenny O’Nions

Jenny O’Nions is a scholar working on Hematology, Oncology and Genetics, having authored 27 papers that have together received 1.2k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (9 papers), Cancer-related Molecular Pathways (7 papers), Viral-associated cancers and disorders (6 papers), Cancer Research and Treatments (4 papers), Multiple Myeloma Research and Treatments (4 papers), Protein Degradation and Inhibitors (4 papers), Lymphoma Diagnosis and Treatment (4 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (3 papers). The work is most often cited by research in Oncology (852 citations), Biotechnology (194 citations) and Cancer Research (175 citations). Jenny O’Nions has collaborated with scholars based in United Kingdom, Australia and United States. Frequent co-authors include Martin J. Allday, Louise Brooks, Tim Crook, John Tidy, María C. Marín, William G. Kaelin, Catherine Harwood, John M. Nicholls, Jane McGregor and Karen H. Vousden. Their work appears in journals such as Nature Genetics, Journal of Clinical Oncology and Blood.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact